|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
AU2008282728B2
(en)
|
2007-08-02 |
2012-04-19 |
Amgen Inc. |
Pl3 kinase modulators and methods of use
|
|
US20100311736A1
(en)
*
|
2007-10-22 |
2010-12-09 |
Glaxosmithkline Llc |
Pyridosulfonamide derivatives as p13 kinase inhibitors
|
|
AU2008343813B2
(en)
|
2007-12-19 |
2012-04-12 |
Amgen Inc. |
Inhibitors of PI3 kinase
|
|
JP5599783B2
(ja)
|
2008-05-30 |
2014-10-01 |
アムジエン・インコーポレーテツド |
Ｐｉ３キナーゼの阻害薬
|
|
JPWO2009157196A1
(ja)
*
|
2008-06-25 |
2011-12-08 |
武田薬品工業株式会社 |
アミド化合物
|
|
WO2010026121A1
(en)
|
2008-09-02 |
2010-03-11 |
Novartis Ag |
Bicyclic kinase inhibitors
|
|
KR20170015566A
(ko)
|
2008-11-10 |
2017-02-08 |
버텍스 파마슈티칼스 인코포레이티드 |
Ａｔｒ 키나제의 억제제로서 유용한 화합물
|
|
WO2010059549A1
(en)
*
|
2008-11-18 |
2010-05-27 |
Glaxosmithkline Llc |
Prolyl hydroxylase inhibitors
|
|
ES2663222T3
(es)
|
2008-12-19 |
2018-04-11 |
Vertex Pharmaceuticals Incorporated |
Derivados de pirazina útiles como inhibidores de la quinasa ATR
|
|
CA2740193A1
(en)
|
2008-12-23 |
2010-07-01 |
Abbott Laboratories |
Anti-viral compounds
|
|
EP2367823A1
(en)
|
2008-12-23 |
2011-09-28 |
Abbott Laboratories |
Anti-viral compounds
|
|
EP2387564A1
(en)
|
2009-01-15 |
2011-11-23 |
Rutgers, The State University of New Jersey |
Benzo ýc¨phenanthridines as antimicrobial agents
|
|
US8815918B2
(en)
|
2009-04-02 |
2014-08-26 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
|
|
CN102459165B
(zh)
|
2009-04-15 |
2015-09-02 |
Abbvie公司 |
抗病毒化合物
|
|
CA2760526A1
(en)
|
2009-04-30 |
2010-11-04 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
HRP20140371T1
(hr)
|
2009-05-15 |
2014-05-23 |
Novartis Ag |
Arilpiridini kao inhibitori sinteze aldosterona
|
|
WO2010135568A1
(en)
|
2009-05-22 |
2010-11-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of mtor and their use to treat cancer
|
|
EP2445902A2
(en)
*
|
2009-06-25 |
2012-05-02 |
Amgen, Inc |
Heterocyclic compounds and their uses as inhibitors of pi3k activity
|
|
PE20121148A1
(es)
|
2009-08-17 |
2012-09-07 |
Intellikine Llc |
Compuestos heterociclicos y usos de los mismos
|
|
WO2011021678A1
(ja)
*
|
2009-08-21 |
2011-02-24 |
武田薬品工業株式会社 |
縮合複素環化合物
|
|
SMT201700026T1
(it)
|
2009-09-03 |
2017-03-08 |
Bristol Myers Squibb Co |
Chinazoline come inibitori dei canali degli ioni potassio
|
|
EP2475375A4
(en)
*
|
2009-09-09 |
2013-02-20 |
Avila Therapeutics Inc |
PI3 KINASE INHIBITORS AND USES THEREOF
|
|
NZ620174A
(en)
|
2009-09-16 |
2016-08-26 |
Celgene Avilomics Res Inc |
Protein kinase conjugates and inhibitors
|
|
MX2012003779A
(es)
*
|
2009-09-28 |
2012-06-01 |
Glaxosmithkline Llc |
Combinacion.
|
|
CN102665720A
(zh)
*
|
2009-10-12 |
2012-09-12 |
葛兰素史密斯克莱有限责任公司 |
组合
|
|
WO2011051958A1
(en)
|
2009-10-30 |
2011-05-05 |
E.I. Du Pont De Nemours And Company |
Fungicidal pyrazolones
|
|
EP2519664A4
(en)
|
2009-12-30 |
2014-03-12 |
Avila Therapeutics Inc |
LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
|
|
JP5856151B2
(ja)
|
2010-05-12 |
2016-02-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
|
|
JP2013529200A
(ja)
|
2010-05-12 |
2013-07-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
JP2013526539A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用なピラジン
|
|
JP2013526540A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
US8969356B2
(en)
|
2010-05-12 |
2015-03-03 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US9630956B2
(en)
|
2010-05-12 |
2017-04-25 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8933096B2
(en)
|
2010-06-09 |
2015-01-13 |
Rugers, The State University of New Jersey |
Antimicrobial agents
|
|
CA2803802A1
(en)
|
2010-06-23 |
2011-12-29 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
|
|
CA2803890A1
(en)
|
2010-06-25 |
2011-12-29 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
ES2565627T3
(es)
*
|
2010-07-30 |
2016-04-06 |
Oncotherapy Science, Inc. |
Derivados de quinolina e inhibidores de MELK que contienen los mismos
|
|
US20130137701A1
(en)
*
|
2010-08-09 |
2013-05-30 |
Tona M. Gilmer |
Combination
|
|
EP2640367A2
(en)
|
2010-11-15 |
2013-09-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
|
US20140080810A1
(en)
|
2010-11-15 |
2014-03-20 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
|
|
JP2013545756A
(ja)
*
|
2010-11-16 |
2013-12-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド |
投与および治療方法
|
|
CA2818544A1
(en)
*
|
2010-11-19 |
2012-05-24 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Method of treatment with braf inhibitor
|
|
WO2012071509A2
(en)
|
2010-11-24 |
2012-05-31 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
|
|
WO2012116237A2
(en)
*
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
SG192769A1
(en)
|
2011-03-04 |
2013-09-30 |
Glaxosmithkline Ip No 2 Ltd |
Amino-quinolines as kinase inhibitors
|
|
US9051305B2
(en)
|
2011-03-08 |
2015-06-09 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
|
CN102718745A
(zh)
*
|
2011-03-30 |
2012-10-10 |
中国科学院上海药物研究所 |
新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
|
|
JP2014510151A
(ja)
|
2011-04-05 |
2014-04-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物
|
|
TW201311683A
(zh)
*
|
2011-04-29 |
2013-03-16 |
Exelixis Inc |
使用吡啶并嘧啶酮ｐｉ３ｋ／ｍｔｏｒ抑制劑治療淋巴瘤之方法
|
|
WO2012178124A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2012178125A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2723745A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
|
WO2013049719A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
SG10201606774UA
(en)
|
2011-09-30 |
2016-10-28 |
Vertex Pharma |
Processes for making compounds useful as inhibitors of atr kinase
|
|
US8853217B2
(en)
|
2011-09-30 |
2014-10-07 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
KR20140084112A
(ko)
|
2011-09-30 |
2014-07-04 |
버텍스 파마슈티칼스 인코포레이티드 |
Ａｔｒ 키나제의 억제제로서 유용한 화합물
|
|
WO2013049859A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
|
|
KR20140088194A
(ko)
|
2011-11-04 |
2014-07-09 |
에프. 호프만-라 로슈 아게 |
아릴-퀴놀린 유도체
|
|
WO2013071094A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US8841337B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
WO2013071088A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US8841450B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
WO2013071085A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
|
DK2790705T3
(en)
|
2011-12-15 |
2018-03-12 |
Novartis Ag |
Use of inhibitors of the activity or function of PI3K
|
|
WO2013106756A2
(en)
|
2012-01-13 |
2013-07-18 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
JP2015509483A
(ja)
*
|
2012-02-06 |
2015-03-30 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ |
線維症を治療するためのｐｉ３ｋ阻害剤
|
|
AU2013218149A1
(en)
|
2012-02-06 |
2014-07-24 |
Glaxosmithkline Intellectual Property (No.2) Limited |
PI3K inhibitors for treating cough
|
|
EP2828245A1
(en)
|
2012-03-21 |
2015-01-28 |
Rutgers, The State University of New Jersey |
Antimicrobial agents
|
|
CA2869309C
(en)
|
2012-04-05 |
2021-02-09 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase and combination therapies thereof
|
|
US20150150869A1
(en)
|
2012-06-20 |
2015-06-04 |
Eutropics Pharmaceuticals, Inc. |
Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
|
|
AR092529A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
|
AR092530A1
(es)
|
2012-09-13 |
2015-04-22 |
Glaxosmithkline Llc |
Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
|
|
CN103497177B
(zh)
*
|
2012-09-29 |
2017-03-22 |
天津滨江药物研发有限公司 |
作为c‑Met抑制剂的氨基芳香杂环类化合物及其制备方法
|
|
US8999632B2
(en)
|
2012-10-04 |
2015-04-07 |
Vertex Pharmaceuticals Incorporated |
Method for measuring ATR inhibition mediated increases in DNA damage
|
|
US8912198B2
(en)
|
2012-10-16 |
2014-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
CN103788071A
(zh)
*
|
2012-11-01 |
2014-05-14 |
中国人民解放军第二军医大学 |
N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途
|
|
EP2922544B1
(en)
|
2012-11-21 |
2018-08-01 |
Eutropics Pharmaceuticals, Inc. |
Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
|
|
SI2941432T1
(en)
|
2012-12-07 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
|
|
RU2662810C2
(ru)
|
2013-02-21 |
2018-07-31 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Хиназолины в качестве ингибиторов киназы
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
CN104098542A
(zh)
*
|
2013-04-11 |
2014-10-15 |
苏州朗信医药科技有限公司 |
一种6-溴代-4-(4-吡嗪基)喹啉的制备方法
|
|
WO2015017788A1
(en)
|
2013-08-01 |
2015-02-05 |
Eutropics Pharmaceuticals, Inc. |
Method for predicting cancer sensitivity
|
|
CN104418858B
(zh)
|
2013-08-30 |
2018-12-11 |
浙江医药股份有限公司新昌制药厂 |
2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
|
|
US9657007B2
(en)
|
2013-09-22 |
2017-05-23 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
|
CN104557955B
(zh)
*
|
2013-10-23 |
2017-05-03 |
上海汇伦生命科技有限公司 |
作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
|
|
WO2015066305A1
(en)
|
2013-10-30 |
2015-05-07 |
Eutropics Pharmaceuticals, Inc. |
Methods for determining chemosensitivity and chemotoxicity
|
|
US9458150B2
(en)
|
2013-11-08 |
2016-10-04 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
JP6496731B2
(ja)
*
|
2013-11-27 |
2019-04-03 |
シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体
|
|
DK3077397T3
(da)
|
2013-12-06 |
2019-12-16 |
Vertex Pharma |
2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
|
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CN104922116B
(zh)
*
|
2014-03-23 |
2020-08-11 |
上海诗丹德生物技术有限公司 |
甲基丙烯酰基苯并咪唑酮衍生物的用途
|
|
NO2714752T3
(https=)
*
|
2014-05-08 |
2018-04-21 |
|
|
|
PL3152212T3
(pl)
|
2014-06-05 |
2020-06-15 |
Vertex Pharmaceuticals Inc. |
Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
|
|
BR112016029825B1
(pt)
|
2014-06-17 |
2020-10-27 |
Cisen Pharmaceutical Co., Ltd. |
composto
|
|
LT3157566T
(lt)
|
2014-06-17 |
2019-08-12 |
Vertex Pharmaceuticals Incorporated |
Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
|
|
EP4578865A3
(en)
|
2014-08-12 |
2025-07-30 |
Monash University |
Lymph directing prodrugs
|
|
CN105330699B
(zh)
*
|
2014-08-13 |
2018-12-04 |
山东汇睿迪生物技术有限公司 |
一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
|
|
WO2016025917A1
(en)
|
2014-08-15 |
2016-02-18 |
Janssen Pharmaceuticals, Inc. |
Triazoles as nr2b receptor inhibitors
|
|
ES2791252T3
(es)
|
2014-08-15 |
2020-11-03 |
Janssen Pharmaceuticals Inc |
Pirazoles
|
|
JP6882978B2
(ja)
|
2014-10-29 |
2021-06-02 |
バイスクルアールディー・リミテッド |
Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
|
|
EP3262049B1
(en)
|
2015-02-27 |
2022-07-20 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
FR3033499A1
(fr)
|
2015-03-11 |
2016-09-16 |
Centre Leon-Berard |
Composition pour le traitement des tumeurs neuroendocrines pancreatiques
|
|
CN104961725B
(zh)
*
|
2015-06-18 |
2017-04-19 |
浙江大学 |
4‑α,β不饱和酰胺基喹啉类化合物及制备和应用
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
HRP20200410T1
(hr)
*
|
2015-07-09 |
2020-08-21 |
Janssen Pharmaceutica Nv |
Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
|
|
JP2018525371A
(ja)
*
|
2015-07-30 |
2018-09-06 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
アリール置換された二環式ヘテロアリール化合物
|
|
WO2017027768A1
(en)
|
2015-08-13 |
2017-02-16 |
The Broad Institute, Inc. |
Compositions and methods for treating tuberculosis
|
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
CA2997106C
(en)
|
2015-09-08 |
2024-06-04 |
Monash University |
Lymph directing prodrugs
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
|
HK1258570A1
(zh)
|
2015-09-30 |
2019-11-15 |
Vertex Pharmaceuticals Inc. |
使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
|
|
HUE061437T2
(hu)
|
2015-10-23 |
2023-06-28 |
Navitor Pharm Inc |
A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai
|
|
US11370792B2
(en)
|
2015-12-14 |
2022-06-28 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of MTHFD2 and uses thereof
|
|
CN108368111B
(zh)
*
|
2015-12-16 |
2020-07-31 |
上海嘉坦医药科技有限公司 |
吡啶并[1,2-a]嘧啶酮类似物的晶型及其制备方法和中间体
|
|
BR112018016329A2
(pt)
|
2016-02-10 |
2018-12-18 |
Janssen Pharmaceutica Nv |
1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
|
|
US10513528B2
(en)
|
2016-02-25 |
2019-12-24 |
Taxis Pharmaceuticals, Inc. |
Synthetic processes and intermediates
|
|
LT3426243T
(lt)
|
2016-03-09 |
2021-08-10 |
Raze Therapeutics, Inc. |
3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas
|
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
CN109640988A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
|
WO2017223243A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
US10154992B2
(en)
*
|
2016-07-12 |
2018-12-18 |
The Regents Of The University Of California |
Compounds and methods for treating HIV infection
|
|
AU2017312970B2
(en)
*
|
2016-08-16 |
2021-08-12 |
Merck Patent Gmbh |
2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
|
|
TW201819376A
(zh)
|
2016-10-06 |
2018-06-01 |
比利時商健生藥品公司 |
經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
|
|
EP3848370B1
(en)
|
2016-10-14 |
2025-05-07 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
|
CN106580986B
(zh)
*
|
2016-11-28 |
2017-09-15 |
王保亮 |
一种治疗少弱精子症的药物组合物
|
|
EP4035659A1
(en)
|
2016-11-29 |
2022-08-03 |
PureTech LYT, Inc. |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
US20180153922A1
(en)
|
2016-12-06 |
2018-06-07 |
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery |
Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
|
|
WO2018115203A1
(en)
|
2016-12-23 |
2018-06-28 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
|
US11534443B2
(en)
|
2016-12-26 |
2022-12-27 |
Institute Of Materia Medica, Chinese Academy Of Medical Sciences |
Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof
|
|
EP3565638B8
(en)
|
2017-01-06 |
2024-04-10 |
BicycleRD Limited |
Bicycle conjugate for treating cancer
|
|
JP7160824B2
(ja)
|
2017-03-08 |
2022-10-25 |
ニンバス ラクシュミ， インコーポレイテッド |
Ｔｙｋ２阻害剤、使用およびその製造のための方法
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
WO2018183917A1
(en)
|
2017-03-30 |
2018-10-04 |
Taxis Pharmaceuticals, Inc. |
Synthetic processes and synthetic intermediates
|
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
US10912750B2
(en)
|
2017-04-26 |
2021-02-09 |
Navitor Pharmaceuticals, Inc. |
Modulators of Sestrin-GATOR2 interaction and uses thereof
|
|
WO2018197893A1
(en)
|
2017-04-27 |
2018-11-01 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
JP7352284B2
(ja)
*
|
2017-05-15 |
2023-09-28 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン |
ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体
|
|
JP7301757B2
(ja)
|
2017-06-26 |
2023-07-03 |
バイスクルアールディー・リミテッド |
検出可能部分を持つ二環式ペプチドリガンドおよびその使用
|
|
KR102717819B1
(ko)
|
2017-07-28 |
2024-10-14 |
다케다 야쿠힌 고교 가부시키가이샤 |
Tyk2 억제제 및 이의 용도
|
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
拜斯科技术开发有限公司 |
Cd137特异性的双环肽配体
|
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
EP3675838A4
(en)
|
2017-08-29 |
2021-04-21 |
PureTech LYT, Inc. |
LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
CN107793404A
(zh)
*
|
2017-11-07 |
2018-03-13 |
全椒先奇医药科技有限公司 |
一种治疗缺血性脑损伤药物组合物及其应用
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3746071A4
(en)
|
2018-01-29 |
2021-09-01 |
Merck Patent GmbH |
GCN2 INHIBITORS AND THEIR USES
|
|
KR20200116481A
(ko)
|
2018-01-29 |
2020-10-12 |
메르크 파텐트 게엠베하 |
Gcn2 억제제 및 이의 용도
|
|
JP2021514953A
(ja)
|
2018-02-23 |
2021-06-17 |
バイスクルテクス・リミテッド |
多量体二環式ペプチドリガンド
|
|
KR20260028873A
(ko)
|
2018-02-27 |
2026-03-04 |
아텍스 바이오파마 인코포레이티드 |
Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
|
|
BR112020018094A2
(pt)
|
2018-03-08 |
2020-12-22 |
Incyte Corporation |
Compostos de aminopirazina diol como inibidores de pi3k-¿
|
|
WO2019193516A2
(en)
|
2018-04-04 |
2019-10-10 |
Janssen Pharmaceutica Nv |
Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
|
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
|
ES2919572T3
(es)
|
2018-04-24 |
2022-07-27 |
Merck Patent Gmbh |
Compuestos antiproliferación y usos de los mismos
|
|
WO2019229765A1
(en)
*
|
2018-05-29 |
2019-12-05 |
Council Of Scientific & Industrial Research, India |
Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof
|
|
EP3575305A1
(fr)
*
|
2018-05-31 |
2019-12-04 |
Biocidal Alternative Solutions |
Procédé de fabrication de composés comprenant un groupe fonctionnel oxazolopyridinones
|
|
CN113194752A
(zh)
|
2018-06-01 |
2021-07-30 |
康奈尔大学 |
Pi3k相关疾病或病症的组合疗法
|
|
IL314362A
(en)
|
2018-06-15 |
2024-09-01 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and their uses
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
KR102595520B1
(ko)
|
2018-07-05 |
2023-10-30 |
엘지디스플레이 주식회사 |
헤테로아릴기를 가진 벤즈아졸 유도체 및 이를 포함하는 유기전계발광소자
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
US12030875B2
(en)
|
2018-09-07 |
2024-07-09 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
|
JP7619951B2
(ja)
|
2018-10-15 |
2025-01-22 |
武田薬品工業株式会社 |
Ｔｙｋ２阻害剤およびその使用
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
CN113164414A
(zh)
|
2018-10-24 |
2021-07-23 |
纳维托制药有限公司 |
多晶型化合物和其用途
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
JP7530360B2
(ja)
|
2018-11-30 |
2024-08-07 |
武田薬品工業株式会社 |
Ｔｙｋ２阻害剤およびその使用
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
US12551567B2
(en)
|
2018-12-21 |
2026-02-17 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for PD-L1
|
|
JP2022514618A
(ja)
|
2018-12-21 |
2022-02-14 |
バイスクルテクス・リミテッド |
Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
|
|
CN120865208A
(zh)
|
2019-01-23 |
2025-10-31 |
武田药品工业株式会社 |
Tyk2抑制剂和其用途
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
TWI875749B
(zh)
|
2019-04-05 |
2025-03-11 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
|
US12304899B2
(en)
|
2019-05-30 |
2025-05-20 |
Merck Sharp & Dohme Llc |
Factor XI activation inhibitors
|
|
WO2020243423A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
MX2021015508A
(es)
|
2019-06-14 |
2022-01-31 |
Janssen Pharmaceutica Nv |
Carbamatos de piridina y su uso como moduladores del receptor glun2b.
|
|
JP7667097B2
(ja)
|
2019-06-14 |
2025-04-22 |
ヤンセン ファーマシューティカ エヌ．ベー． |
置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
|
|
KR20220024403A
(ko)
|
2019-06-14 |
2022-03-03 |
얀센 파마슈티카 엔.브이. |
치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
|
|
AU2020293642A1
(en)
|
2019-06-14 |
2022-01-20 |
Janssen Pharmaceutica Nv |
Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
|
|
CN113993868A
(zh)
|
2019-06-14 |
2022-01-28 |
詹森药业有限公司 |
取代的吡唑并吡啶酰胺以及它们作为glun2b受体调节剂的用途
|
|
CN113950357A
(zh)
|
2019-06-14 |
2022-01-18 |
詹森药业有限公司 |
吡嗪氨基甲酸酯及其作为GluN2B受体调节剂的用途
|
|
SG11202112405VA
(en)
|
2019-06-14 |
2021-12-30 |
Janssen Pharmaceutica Nv |
Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
JP7842684B2
(ja)
|
2019-09-11 |
2026-04-08 |
ビンシア・バイオサイエンシーズ・インコーポレイテッド |
Ｕｓｐ３０阻害剤及びその使用
|
|
CN114945366B
(zh)
|
2019-09-13 |
2025-01-07 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
CA3156436A1
(en)
|
2019-11-01 |
2021-05-06 |
Steven LEVENTER |
Methods of treatment using an mtorc1 modulator
|
|
KR20220128345A
(ko)
|
2019-12-05 |
2022-09-20 |
아나쿠리아 테라퓨틱스, 인코포레이티드 |
라파마이신 유사체 및 이의 용도
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
BR112022012410A2
(pt)
|
2019-12-23 |
2022-08-30 |
Kymera Therapeutics Inc |
Degradadores smarca e usos dos mesmos
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
CN115348864A
(zh)
|
2020-02-05 |
2022-11-15 |
纯技术Lyt股份有限公司 |
神经甾体的脂质前药
|
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
US12528785B2
(en)
|
2020-03-19 |
2026-01-20 |
Kymera Therapeutics, Inc. |
MDM2 degraders and uses thereof
|
|
TWI904146B
(zh)
*
|
2020-03-31 |
2025-11-11 |
美商卡默森屈有限公司 |
使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法
|
|
WO2021247897A1
(en)
|
2020-06-03 |
2021-12-09 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
IL300248A
(en)
|
2020-08-03 |
2023-03-01 |
Bicycletx Ltd |
peptide-based linkers
|
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
US12331046B2
(en)
|
2020-10-23 |
2025-06-17 |
Nimbus Clotho, Inc. |
CTPS1 inhibitors and uses thereof
|
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
PH12023500015A1
(en)
|
2020-12-30 |
2024-03-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP4288427A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
CN117120090A
(zh)
|
2021-02-12 |
2023-11-24 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
EP4295850A4
(en)
|
2021-02-16 |
2025-03-05 |
Ribotech Co., Ltd. |
COMPOUND FOR INHIBITING NONSENSE-MEDIATED mRNA DEGRADATION
|
|
EP4301756A4
(en)
|
2021-03-05 |
2025-02-26 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
WO2022194248A1
(zh)
*
|
2021-03-18 |
2022-09-22 |
苏州国匡医药科技有限公司 |
Ctla-4小分子降解剂及其应用
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
AU2022256074A1
(en)
|
2021-04-09 |
2023-11-02 |
Nimbus Clio, Inc. |
Cbl-b modulators and uses thereof
|
|
JP2024514879A
(ja)
|
2021-04-16 |
2024-04-03 |
イケナ オンコロジー， インコーポレイテッド |
Ｍｅｋ阻害剤及びその使用
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
CN115353512B
(zh)
*
|
2021-07-30 |
2025-07-08 |
上海翊石医药科技有限公司 |
一种杂环脲类化合物及其制备方法和用途
|
|
CN113416181B
(zh)
*
|
2021-08-02 |
2022-05-03 |
四川大学 |
喹唑啉类衍生物及其用途
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
JP2024534127A
(ja)
|
2021-08-25 |
2024-09-18 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|
|
WO2023046182A1
(zh)
*
|
2021-09-27 |
2023-03-30 |
广州嘉越医药科技有限公司 |
一种吡啶并[1,2-a]嘧啶酮类化合物的应用
|
|
US12187744B2
(en)
|
2021-10-29 |
2025-01-07 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and synthesis thereof
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
IL316768A
(en)
|
2022-05-25 |
2025-01-01 |
Ikena Oncology Inc |
MEK inhibitors and their uses
|
|
WO2024012534A1
(zh)
*
|
2022-07-13 |
2024-01-18 |
武汉人福创新药物研发中心有限公司 |
杂环并苯环类化合物及其制备方法和用途
|
|
JP2025527247A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
|
|
IL318575A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
|
|
CN120051456A
(zh)
|
2022-08-02 |
2025-05-27 |
里米诺生物科学有限公司 |
取代的吡啶酮gpr84拮抗剂及其用途
|
|
CN120457127A
(zh)
*
|
2022-10-20 |
2025-08-08 |
麦克尼斯迪克治疗有限公司 |
用于调节egfr和pi3k的化合物
|
|
US20240208961A1
(en)
|
2022-11-22 |
2024-06-27 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CN116239594B
(zh)
*
|
2023-03-05 |
2023-09-22 |
贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) |
6-(咪唑并[1,2-a]吡啶-6-基)喹唑啉衍生物及用途
|
|
IL321486A
(en)
|
2023-06-23 |
2025-08-01 |
Kymera Therapeutics Inc |
Iraqi joints and their uses
|
|
WO2025045915A1
(en)
*
|
2023-08-29 |
2025-03-06 |
Institut National de la Santé et de la Recherche Médicale |
Methods for inducing muscle hypertrophy
|
|
WO2025062372A1
(en)
|
2023-09-21 |
2025-03-27 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|
|
CN118126038B
(zh)
*
|
2024-05-08 |
2024-07-12 |
烟台大学 |
吡唑并吡啶类衍生物及其制备方法和应用
|